Skip to main content
Figure 3 | BMC Medicine

Figure 3

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

Figure 3

Overall survival, Kaplan-Meier survival estimate. A, c.35 G > A KRAS mutant patients versus other KRAS mutant plus KRAS wild-type patients; B, c.35 G > A KRAS mutant patients versus KRAS/BRAF wild-type patients; C, c.35 G > A KRAS mutant patients versus other codon 12 KRAS mutant patients; D, c.35 G > A KRAS mutant patients versus c.35 G > T KRAS mutant patients.

Back to article page